Literature DB >> 24257941

Serum zinc and copper in hyperlipoproteinemia.

G Uza1, S Gabor, A Kovats, R Vlaicu, M Cucuianu.   

Abstract

Starting from experimental observations demonstrating that a high ratio of zinc to copper led to hypercholesterolemia in rats, serum Zn and Cu levels were measured by atomic absorption spectrophotometry in 65 normolipemic controls and in 100 subjects with various types of hyperlipoproteinemia (HLP). Serum Zn levels did not significantly differ from control values in any type of HLP. However, hyperlipoproteinemic patients with obvious clinical atherosclerosis displayed significantly lower serum-Zn concentration than hyperlipo-proteinemic subjects without clinical symptoms. On the other hand, when compared to control subjects, serum Cu levels were not found to be decreased, but rather increased, in hyperlipoproteinemic patients with or without atherosclerosis. As a result, the ZnCu ratio appeared to be lower than normal in hyperlipoproteinemic patients with cardiovascular disease. It is conceivable that changes of these trace elements should be rather connected to vessel injury and associated disease than to HLP which, at least in humans, is not accompanied by a high ZnCu ratio.

Entities:  

Year:  1985        PMID: 24257941     DOI: 10.1007/BF02917455

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  10 in total

1.  Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia.

Authors:  M Cucuianu; T A Popescu; A Opincaru; S Hărăgus
Journal:  Clin Chim Acta       Date:  1975-02-22       Impact factor: 3.786

2.  Blood zinc levels in patients with arteriosclerosis obliterans, thromboangiitis obliterans and Takayasu's disease.

Authors:  T Atsumi; F Numano
Journal:  Jpn Heart J       Date:  1975-11

3.  Serum protein changes during the acute phase reaction.

Authors:  M Werner
Journal:  Clin Chim Acta       Date:  1969-08       Impact factor: 3.786

4.  Elements of ischemic heart disease.

Authors:  L M Klevay
Journal:  Perspect Biol Med       Date:  1977 WINTER       Impact factor: 1.416

Review 5.  Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia.

Authors:  J L Goldstein; T Kita; M S Brown
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

6.  Cholesterolemia and cardiovascular abnormalities in rats caused by copper deficiency.

Authors:  K G Allen; L M Klevay
Journal:  Atherosclerosis       Date:  1978-01       Impact factor: 5.162

7.  Dilute blood clot lysis time and electrophoretic lipoprotein fractions in a population sample of healthy Romanians.

Authors:  T A Popescu; C Stef; G Moraru; M P Cucuianu
Journal:  Atherosclerosis       Date:  1977-06       Impact factor: 5.162

8.  Zinc lowers high-density lipoprotein-cholesterol levels.

Authors:  P L Hooper; L Visconti; P J Garry; G E Johnson
Journal:  JAMA       Date:  1980 Oct 24-31       Impact factor: 56.272

9.  [Copper pathology (author's transl)].

Authors:  B Mallet; J Romette; J D Di Costanzo
Journal:  Nouv Presse Med       Date:  1982-01-30

10.  Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.

Authors:  W C Breckenridge; J A Little; G Steiner; A Chow; M Poapst
Journal:  N Engl J Med       Date:  1978-06-08       Impact factor: 91.245

  10 in total
  3 in total

1.  Serum copper and zinc in industrial centers in Slovakia.

Authors:  T Magalova; A Brtkova; A Bederova; I Kajaba; I Puchonova
Journal:  Biol Trace Elem Res       Date:  1994-03       Impact factor: 3.738

2.  Serum zinc and copper in patients with atherosclerosis and thromboangiitis obliterans.

Authors:  G Uza; R Vlaicu
Journal:  Biol Trace Elem Res       Date:  1989-06       Impact factor: 3.738

3.  Atherosclerotic lesion-specific copper delivery suppresses atherosclerosis in high-cholesterol-fed rabbits.

Authors:  Na Wang; Xinwen Xu; Hualin Li; Qipu Feng; Hongge Wang; Y James Kang
Journal:  Exp Biol Med (Maywood)       Date:  2021-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.